MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective

Summary Background The World Health Organization (WHO) set a goal to eliminate hepatitis C (HCV) infection globally by 2030, with specific targets reduce new viral infections 80% and related deaths 65%. However, an overlooked aspect that may hinder these efforts is the impact other liver diseases could have continuing drive disease progression offset beneficial of DAAs on end‐stage hepatocellular carcinoma (HCC). In particular, decrease in HCV prevalence has been countered marked increase metabolic‐associated fatty (MAFLD). Aims To review potential interaction MAFLD. Methods We reviewed literature relating arrange HCV, metabolic dysfunction Results this viewpoint, international experts suggest holistic multidisciplinary approach for management growing number treated patients who achieved SVR, taking into consideration MAFLD reducing morbidity mortality people had HCV. Conclusions This will strengthen improve continuum care cascade disease(s) holds alleviate cost burden disease; quality life following treatment.